000			02026 a2200505 4500
005			20250517080458.0
264		0	_c20170116
008			201701s 0 0 eng d
022			_a1878-7479
024	7		_a10.1007/s13311-016-0420-z _2doi
040			_aNLM _beng _cNLM
100	1		_aOrefice, Nicola S
245	0	0	_aOral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. _h[electronic resource]
260			_bNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics _cApr 2016
300			_a428-38 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAmides
650	0	4	_aAnti-Inflammatory Agents _xadministration & dosage
650	0	4	_aCytokines _xblood
650	0	4	_aDisease Progression
650	0	4	_aDouble-Blind Method
650	0	4	_aEthanolamines _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInterferon beta-1a _xadverse effects
650	0	4	_aInterferon-gamma _xblood
650	0	4	_aInterleukin-17 _xblood
650	0	4	_aMale
650	0	4	_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy
650	0	4	_aPalmitic Acids _xadministration & dosage
650	0	4	_aSkin _xdrug effects
650	0	4	_aTumor Necrosis Factor-alpha _xblood
700	1		_aAlhouayek, Mireille
700	1		_aCarotenuto, Antonio
700	1		_aMontella, Silvana
700	1		_aBarbato, Franscesco
700	1		_aComelli, Albert
700	1		_aCalignano, Antonio
700	1		_aMuccioli, Giulio G
700	1		_aOrefice, Giuseppe
773	0		_tNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics _gvol. 13 _gno. 2 _gp. 428-38
856	4	0	_uhttps://doi.org/10.1007/s13311-016-0420-z _zAvailable from publisher's website
999			_c25714337 _d25714337